Lembore exant

Structural formula
General
Non-proprietary name	Lembore exant
other names	Dayvigo, E-2006
Molecular formula	C 22 H 20 F 2 N 4 O 2
External identifiers / databases
CAS number 1369764-02-2 PubChem 56944144 ChemSpider 34500836 DrugBank DB11951 Wikidata Q20707990
Drug information
Drug class	Hypnotic
properties
Molar mass	410.425 g mol −1
Physical state	firmly
safety instructions
GHS labeling of hazardous substances no GHS pictograms H and P phrases H: no H-phrases P: no P-phrases
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Lemborexant is a drug used to treat sleep disorders. Lemborexant was developed by Eisai and approved by the FDA in 2019 .

Working principle

Lemborexant is a dual antagonist of the OX1 and OX2 receptors.

Indications

Lemborexant is indicated for the treatment of insomnia (difficulty falling asleep and / or staying asleep).

Contraindications

Lemborexant must not be used if you have narcolepsy .

Side effects

The most commonly reported side effects of lemborexant are somnolence , headache, and flu-like symptoms.

Individual evidence

1. ↑ ^{a b} Lemborexant-SDS , accessed April 14, 2020
2. ^ Novel Drug Approvals for 2019 . FDA .
3. ↑ Lemborexant: First Approval. In: Drugs. 2020, doi : 10.1007 / s40265-020-01276-1 . PMID 32096020 .
4. ↑ ^{a b} DAYVIGO- lemborexant tablet, film coated . DailyMed .
5. ↑ Russell Rosenberg, Patricia Murphy, Gary Zammit, David Mayleben, Dinesh Kumar, Shobha Dhadda, Gleb Filippov, Antonia LoPresti, Margaret Moline: Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial . In: JAMA network open . tape 2 , no. 12 , 2019, ISSN  2574-3805 , p. e1918254 , doi : 10.1001 / jamanetworkopen.2019.18254 , PMID 31880796 , PMC 6991236 (free full text).
6. ↑ Lemborexant • ARZNEI-NEWS. In: arznei-news.de. Retrieved April 15, 2020 .